On May 10, 2021 Promega Corporation reported that Serious runners and casual walkers alike are invited to join a month-long Get Your Rear in Gear – Madison run/walk virtual event during May to raise money and awareness for colorectal cancer screening efforts (Press release, Promega, MAY 10, 2021, View Source [SID1234579609]). Colorectal cancer is the nation’s No. 2 cancer killer, but it is up to 95% preventable with proper screening. The number of people being screened has dropped drastically worldwide since the start of the COVID-19 pandemic. The event is aimed to help encourage this important, life-saving health screening.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is imperative that patients are encouraged to get back in with their primary doctor to get screening tests they may have missed," says Dr. Sam Lubner, an oncologist at the University of Wisconsin Carbone Cancer Center. "Without accurate diagnosis as early as possible, all of the advancements we have made in cancer research cannot be brought to bear for patients."

Get Your Rear in Gear – Madison is presented by Promega and Exact Sciences with the support of the Colon Cancer Coalition. This inaugural event is one of nearly 40 held annually across the country planned by local volunteers. Money raised will go to UW Carbone Cancer Center programs aimed at increasing colon cancer screening and early detection.

Registration is open during the entire month of May at www.ColonCancerCoalition.org/Madison. Event participation for colorectal cancer patients and survivors is free. Fundraising by participants is encouraged, but not required.

On May 10, 2021 Centessa Pharmaceuticals ("Centessa") reported that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer (Press release, Centessa Pharmaceuticals, MAY 10, 2021, View Source [SID1234579608]). Dr. Yver is one of the world’s leading drug developers with more than 30 years of global experience in the pharmaceutical industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are absolutely thrilled to welcome Antoine to our team as CMO," said Saurabh Saha, M.D., Ph.D., Chief Executive Officer of Centessa. "Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world. I look forward to partnering with him as we advance our portfolio of preclinical programs into the clinic and progress our four assets currently in clinical development."

"I am delighted to be joining Centessa, a differentiated company with a unique operating model," said Dr. Yver. "Centessa’s asset-centric model exemplifies the very best practices that I have experienced and implemented in the industry. I am honored to be working with such a talented leadership team and exceptional Board and look forward to helping establish this bold new R&D enterprise while we strive to bring important new medicines to patients."

Dr. Yver brings more than 30 years of global experience in the pharmaceutical industry to Centessa and has played a pivotal role in the development and approvals of 11 different drugs, including Tagrisso, Lynparza, and Enhertu. He led the development of Tagrisso in 2 years 7 months from first human dose to U.S. approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Dr. Yver joins the company from Daiichi Sankyo, where he served as Executive Vice President and Global Head, R&D Oncology, and Chair of the Cancer Enterprise. Previously, Dr. Yver was with AstraZeneca, most recently serving as Senior Vice President, Global Medicine Head, Oncology, and Global Medicines Development China Lead. Earlier, he held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc, Applied Immune Sciences, Inc, and Chugai-RP. Dr. Yver is a pediatric oncologist and holds an M.D. from Université Paris-Saclay.

On May 10, 2021 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) reported that TREAKISYM RI (50ml) liquid formulation has been filed with the Pharmaceuticals and Medical Devices Agency ("PMDA") in Japan (Press release, Eagle Pharmaceuticals, MAY 10, 2021, View Source [SID1234579607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application is based on the results of clinical studies investigating the safety and pharmacokinetics of TREAKISYM RTD administered by 10-minute intravenous infusion.

"We are pleased that the RI application has been submitted ahead of schedule, which will enable patients and providers alike to reap the benefits of this formulation. We believe we can get close to peak income of $20-$25 million as early as next year from the RTD and RI products. This is an important extension of the bendamustine franchise, and we value the relationship with Symbio," stated Scott Tarriff, Chief Executive Officer.

In September 2017, Eagle licensed to SymBio intellectual property necessary to develop, market and sell RTD and RI formulations of bendamustine under the trade name TREAKISYM in Japan utilizing Eagle’s proprietary technology. As part of the agreement, SymBio assumed responsibility for securing regulatory approval of the TREAKISYM RTD and RI products using the licensed technology in Japan.

TREAKISYM RI has the advantage of reducing infusion time to 10 minutes (from the current 60 minutes), eliminating the need for manual reconstitution and significantly reducing preparation time, benefitting both patients and healthcare providers.

On May 10, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET (Press release, Vertex Pharmaceuticals, MAY 10, 2021, View Source [SID1234579606]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company’s website.

On May 10, 2021 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported that the Company intends to release its first quarter 2021 financial results on Monday, May 17, 2021 (Press release, Onconova, MAY 10, 2021, View Source [SID1234579605]). Management plans to host a conference call and live webcast at 4:30 p.m. ET on that day to discuss these results and provide an update on its pipeline programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information
Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers and using conference ID 4895447.

Those interested in listening to the conference call via the internet may do so by visiting the investors and media page on the company’s website at www.onconova.com and clicking on the webcast link. In addition to the live webcast, a replay will be available on the Onconova website for 90 days following the call.